Who we are
Company timeline
2023
Awards
Investments
Orchard Therapeutics announces strategic financing totalling up to $188m.
View articleSpinouts
Asite acquires 3D Repo
View articleAnniversary
UCLB celebrates 30 years
View Article2022
Biopharm advancements
BioMarin announces stable and durable annualised bleed control in the largest Phase 3 gene therapy study in adults with severe Haemophilia A.
View article
Orchard Therapeutics announces historic agreement making Libmeldy available by NHS England for MLD patients.
View article
First gene therapy for adults with severe Haemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), approved by European Commission (EC)
View article
Freeline initiates dosing of second cohort in MARVEL-1 trial of FLT190 gene therapy candidate for people with Fabry disease
View articleInvestments
Bramble Energy secures £35m
Series B investment round to continue its development of hydrogen fuel cells.
View articleCollaborations
Engitix announces expanded collaboration and licensing agreement with Takeda to develop new anti-fibrotic therapies in Inflammatory Bowel Disease.
View articleSpinouts
Bloomsbury Genetic Therapies launches with Seed financing of £5m to develop potentially curative gene therapy treatments for rare neurological and metabolic diseases.
View article2021
Spinouts
UCLB spinout, Senceive, is acquired by Eddyfi/NDT.
View article
Achilles Therapeutics announces its IPO on NASDAQ.
View article
UCL spinout, Satalia is acquired by WPP, the world's largest advertising firm.
View articleInvestments
Apollo Therapeutics raises £100m
Series A funding to rapidly advance cutting-edge science.
View articleBramble Energy secures £5m
Series A investment to support the launch of its zero-emissions portable power product range.
View article
Carbon Re secures £1m
seed funding to help energy-intensive industries achieve Net Zero.
View articleLaunches
Axovia Therapeutics, backed by Deerfield Management Co., launched to develop transformative medicines for ciliopathies.
View articleAwards
UCLB's CEO, Anne Lane, receives a Lifetime Achievement Award in recognition of her commitment to commercialisation throughout her career.
View articleApollo Therapeutics wins Praxis Auril KE Deal of the Year, for attracting major investment to empower a unique, multi-university portfolio-based biopharmaceuticals venture.
View articleBiopharm advancements
NovalGen doses its first patient in Phase I study in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma.
View article2020
Investments
Freeline receives further $80m
from Syncona in its Series C funding round, to develop curative gene therapies for chronic systemic diseases.
View article
UCLB and Apollo Therapeutics secure first out-licensing deal to Deerfield, a leading U.S. healthcare investment firm.
View article
Humanloop raises funding to teach AI to learn from humans faster.
View article
UCL Technology Fund announces first close of £100m
Fund 2.
View articleAdvancements
UCL-Ventura CPAP device.
UCL supports worldwide dissemination of free-to-access manufacturing instructions for COVID-19 breathing aids.
View article
UCLB wins Knowledge Exchange External Initiative of the Year, for its global dissemination of the UCL-Ventura breathing aid.
View articleSocial venture
UCL artist, Onya McCausland launches paint made from coal mine waste.
View articleBiopharm advancements
Orchard Therapeutics makes progress in its mission to help people with rare diseases.
Orchard announces FDA-granted orphan drug designation for OTL-102 for the treatment of X-linked Chronic Granulomatous Disease.
View article
Orchard announces first patient dosed with OTL-201 gene therapy in Proof of Concept clinical trial.
View articleSpinouts
Freeline Therapeutics makes its NASDAQ debut, raising $158.8m
IPO.
View articleAwards
Two UCLB spinout companies announced winners at the SEHTA MedTech Business Awards.
View article2019
Social venture
UCLB launches funding for early-stage social ventures.
Watch video
NHS England provides online support, developed at UCL, for type 2 diabetes.
View articleInvestments
QuellTx raises £35m
Series A financing, backed by Syncona.
View articleEchopoint raises £2.8m
to address the 'grey zone' of heart disease treatment.
View articleAchilles Therapeutics raises £100m
in oversubscribed Series B financing round.
View article
£6.5m
of funding for spinout, AstronauTx for dementia research.
View articleAnnouncements
Dr Anne Lane appointed as new Managing Director for UCLB.
View articleAwards
Four UCLB spinout companies are named finalists in the European Lifestars Awards: Ixico, Orchard Therapeutics, Quell Therapeutics, Autolus Therapeutics.
View articleBiopharm advancements
Development of a new gene therapy for the treatment of haemophilia A, licensed to BioMarin, on track.
View article2018
Spinouts
UCLB spinouts raise a total of $460.9m in their IPOs on NASDAQ.
Autolus Therapeutics IPO
View articleOrchard Therapeutics IPO
View article
Meira GTx IPO
View articleSpinouts
Orchard Therapeutics acquires rare disease gene therapy portfolio from GSK.
View articleAnnouncements
Investments
Freeline secures over £88m
Series B funding to drive its programmes through clinical development.
View articleOrchard Therapeutics announces $150m
Series C financing to advance gene therapy pipeline.
View article
Engitix closes £5m
Series A financing to progress liver disease and pancreatic cancer treatment.
View article
Endomag secures $10m
Series C funding to establish better breast cancer care.
View articleAwards
UCLB spinout Endomag wins two prestigious awards: The Queen's Award for Enterprise in Innovation, Institute of Physics' British Business Innovation Award.
View articleOrchard Therapeutics win GUV Deal of the Year Award, for its oversubscribed $110m Series B funding round.
View article2017
Biopharm advancements
BioMarin provides 1.5 years of clinical data for Valoctocogene Roxaparvovec gene therapy for severe haemophilia A, developed by Prof. Amit Nathwani, UCL Cancer Institute.
View article
First patient treated in trial of a novel liver dialysis device, DIALIVE.
View articleInvestments
Apollo Therapeutics launches its first four drug discovery programmes in collaboration with academics at all three partner universities, spanning a variety of disease areas and drug modalities.
View articleOrchard Therapeutics announces $110m
Series B financing to advance transformative gene therapy pipeline.
View articleAutolus secures $80m
Series C funding to establish clinical proof of concept for three novel haematological cancer programmes.
View articleSpinouts
UCLB spinout company Puridify acquired by GE Healthcare.
View articleCollaborations
UCLB spinout Chirp collaborates with Hijinx to bring toys to life.
View article2016
Launches
£50m
UCL Technology Fund launched to support academics whose research has commercial potential.
View article£40m
Apollo Therapeutics Fund launched to drive therapeutic innovation.
View articleAdvancements
Research into a potential cure for blindness.
View articleBiopharm advancements
BioMarin provides positive data from its Phase 1/2 clinical trial, showing that patients with haemophilia A had improved and sustained clotting function.
View articleInvestments
Achilles Therapeutics raises £13.2m
Series A funding to develop immunotherapies for cancer.
View articleAutolus secures £40m
Series B funding to develop its proprietary pipeline of engineered T-cell products.
View article2015
Investments
Yaqrit receives £2m
Series A investment to deliver new treatments for liver disease.
View article
Abcodia secures £5.25m
Series B funding to help early detection of ovarian cancer.
View articlePuridify completes £2.2m
Series A funding round for the progression of its proprietary nanofibre purification platform.
View article
MediaGamma secures seed funding to bring new trading methodologies and products to the programmatic digital advertising sector.
View articleBiopharm advancements
BioMarin enrols first patient in Phase 1/2 trial of gene therapy drug for the treatment of haemophilia A.
View articleSpinouts
Five spinout companies launched.
Autolus Therapeutics receives £30m
investment from Syncona.
View articleYaqrit wins €6m
grant award from the EU.
View articleOrchard Therapeutics secures £21m
in Series A financing led by F-Prime.
View article
Athena Vision receives $5m
investment from Kadmon Gene Therapy Holdings Ltd.
View articleFreeline Therapeutics receive £25m
investment from Syncona.
View articleCollaborations
UCLB and Cycle Pharmaceuticals enter into partnership to repurpose drugs for liver diseases.
View article2014
Awards
UCL rated top UK university by research strength in the REF2014.
View articleCollaborations
Helicon Health and Inhealthcare join forces to improve stroke prevention.
View article
UCLB signs exclusive global licence with BioKier Inc. for treatment of metabolic diseases.
View articleInvestments
Autolus raises £30m
in Series A financing round, backed by Syncona and UCLB, for the development of cancer immunotherapies.
View articleBiopharm advancements
UCL professors working with UCLB develop a stem cell transplantation therapy which could restore sight.
View articleSocial venture
Health Social Innovators Fund launches with backing from the Cabinet Office to support early-stage social ventures.
View articleAnnouncements
